Stats

The market closed at 16:30 with zero allocation. The current delivery for job33 is unverified. The goal is to achieve repeatable net gains before events. There are three premises: (1) the queried ledger shows all trades are closed with no pending or open trades, and 20 monitors show no issues until the next run on September 7 at 00:00 UTC. (2) The New York Stock Exchange website lists September 7 as a holiday, and Chewy's fiscal second-quarter financial results conference call is scheduled for September 9 at 8:00 ET, leaving only one regular session. (3) A backtest using vectorbt showed a 1.719988% loss, with a 14.258614% drawdown, and a 95% mean confidence interval of -4.527052% to 3.687206%. The Python expectancy is -0.152652% per 9-session exposure. (4) Technical analysis showed a risk-to-reward ratio of 1.0337, which is less than 1.5. The conclusion is that there are no proposals. The validity of the conclusion is based on the required entry conjunction failing. The soundness of the conclusion is limited by the small sample size and the use of historical data. A counterexample could be a favorable future report or rally, but it cannot establish an edge. The evidence required to change the size of the allocation is a preregistered comparable net holdout with positive expectancy and fresh executable levels. The beneficiary of the cash allocation is the future book optionality, and the operator's shortfall does not change the probability. The consequence of an unvalidated holiday limit is a possible pre-news fill, adverse binary gap, and smaller future book. Cash avoids this exposure but forgoes possible upside. Saved jobs 30 and 33 contain the end of the data, and job 33 is still running. There are no overdue events or exposures, so the duplicate collector is not necessary. Existing monitors will keep the favorable and adverse branches. Other fund FIVE's overdue monitor belongs to the CIO, not Catalyst.

The automated trading fund manager started with $49.14 in cash and an account balance of $850.99, with no open or pending orders. The goal is to achieve repeatable net gains before events. The manager confirmed that the New York Stock Exchange will be closed on September 7, and that Chewy will announce its fiscal second-quarter financial results on September 9 before the market opens. A backtest using vectorbt had 12 training sessions and 6 holdout sessions, with approximate round-trip costs of 20 basis points, and resulted in a holdout return of -1.719988%, a drawdown of 14.258614%, and a win rate of 50%. The manager decided not to propose any new trades, exits, or adjustments, and to retain cash to preserve future options. The decision was based on the lack of validated edge and the potential risks of exposure to holiday trading. The manager will continue to monitor the market, but no new backtests or monitors are warranted at this time.

The last output of Job24 was cut short before TSM and HITI/BFRI, which refers to a type of investment tracking system, and all future branches remain in the journal but the collector was not delivering the claimed coverage. This issue was resolved by replacing it with accepted Job30, which had 720 minutes and 64 runs, and then canceling Job24. A local test was done to preserve 2 filing checks and 5 source-linked reminders with an END marker, which is a signal to stop a process. A new job, Job33, was accepted with 240 minutes and 24 runs, and a local test of 1554 bytes was done, which collects data from TLX, AVO, ABMRSS, and UNFI, with a fallback option. The initial name validation rejection was retried successfully. AVO set monitor 422 was armed at 20, but no new armed AVO monitor was claimed. The first sandbox outputs are not yet available, and the next run on September 7 at 00 UTC must verify END markers and error states. The existing active list from September 17 and 27 was truncated, but the leading current headlines are only for discovery, not complete primary surveillance. This change affects collection reliability, not investment edge. The sources used include the actual list of jobs from the fund catalyst and tested script outputs, as well as primary feed URLs from Telix Pharma, Mission Produce, and ABM, and SEC filings from the Securities and Exchange Commission website. On September 9, the macro read-only branches in analysis 432 and note 405 were reviewed, and it was decided to record and validate good new data, and to take no action on adverse data. No orders or stop automation were made, and all cash will be held until an independent edge is established. Static reminders are not live calendar re-verifications. The limits are set to the latest item only, with a 4-hour cadence, and missing IR feed and unverified saved first execution are explicit.

This is a review of past technical analysis, not new research or testing. On September 4, the closing price of CHWY was 23.67, with a 20-day moving average of 23.35 and a 50-day moving average of 22.25, and an average daily range of 0.88125. The 20-day low was 21.965. A target price of 25.4325 was calculated, with a risk-to-reward ratio of 1.0337, which is below 1.5. The market is currently closed, and these prices are from Friday, not Tuesday. Simply adjusting the stop-loss to fit the technical analysis does not make the trade valid. Even buying two whole shares at 47.34, below the fund's cash level of 49.14, does not fix the failed trade or missing one-session edge. The release of earnings by UNFI and ABM on the morning of September 8, before the first regular trading session, means that any overnight limit orders could be executed before the news is released, without a valid entry or exit point. Therefore, no orders were placed. After the close on September 8, the trade could have run up to the same level as the regular session, but there is no rule to exit the trade before the news is released. Since there are no holdings, there are no stops or targets that need to be adjusted. Theoretical levels are not the same as actual orders. A claim for a gap-bounded risk was rejected, with a realized loss of -6.4403R. The source data can be found at the following links: https://runway.adityaperswal.workers.dev/data/stock-bars, https://investor.chewy.com/news-and-events/news/news-details/2026/Chewy-Announces-Fiscal-Second-Quarter-Financial-Results-Conference-Call/default.aspx, https://abm.gcs-web.com/news-releases/news-release-details/abm-announce-third-quarter-2026-financial-results, https://ir.unfi.com/events/default.aspx, and https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial. There is no need to re-run the analysis, as the rule has already been rejected, and a generic momentum result would not answer the specific question about the one-session trade.

The plan for September 8-9 pre-open has been confirmed. The account starts with $850.99 in cash and a goal to repeat net pre-event gains. The binding constraint is independently supported by an executable edge, which is not a $349.01 monthly shortfall. There are several premises: the NYSE holiday on September 7 means the next sessions are on September 8 and 9. On September 8, there are morning events for UNFI and ABM, and after-close events for BRZE, CASY, and AVO. GME has a complete date on September 8, which was pre-announced. On September 9, there are before-open events for CHWY and ASO, and a date-only event for Inditex. Full issuer URLs and dates have been recorded for observations 7023-7031, including a new announcement from AVO. UNFI and ABM have zero remaining regular pre-release entry sessions, while others have at most one US session before the first news. The plan also includes a saved CHWY fixed 10-session holdout with a return of -1.719988%, and a new AVO Calavo acquisition that makes historical comparability uncertain. Official macro events are scheduled for September 8 at 10 ET, including QFR manufacturing, mining, wholesale, services, and retail, as well as G19 consumer credit at 15 ET. On September 9, there are events at 10 ET for EC and QSS. There are no verified FDA deadlines on September 8 or 9. Early decisions remain possible. The conclusion is to propose zero orders, with no stops needed on a flat book and no queued holiday limits. The validity of the plan is necessary, but soundness is bounded by partial calendar coverage, censored live trades, small holdout, and unverified execution data. This plan does not predict bad earnings or universal run-up failure. There have been changes to the primary date and news, as well as the prospective independent test. Existing Catalyst monitors are not due, and a new AVO monitor has been rejected. There are no entries or automatic executions planned.

The following points outline potential changes in the market. Firstly, consumer credit expansion or contraction on September 8 may affect household financing, which could lead to different demand expectations for discretionary ASO and recurring CHWY, a type of online retail, demand. Any price response must be distinguished from company-specific earnings on September 9. Credit growth alone does not necessarily indicate healthy consumption or financial distress, referring to a state of financial difficulty. Secondly, employer compensation cost data on September 9 at 10 ET, or 10 am Eastern Time, may change labor-cost expectations, which could affect ABM contract repricing and productivity economics after its September 8 report. Margin and cash prospects may diverge from headline revenue, meaning the actual financial performance may differ from the reported revenue. The June period data is lagged, not live September payroll pressure, meaning it is outdated and does not reflect the current situation. Thirdly, AVO recovery in fruit-size supply and per unit margin could lead to acquisition integration cash and debt service, resulting in sustainable earnings per new share. Gross volume or nominal acquisition revenue alone does not complete the chain, referring to the need for a comprehensive analysis. Distributors may gain only if the gross spread survives procurement and logistics costs, while growers and retailers may capture other parts. Fourthly, a favorable Pixclara decision could lead to label, reimbursement, and manufacturing constraints, resulting in realized Telix cash. An early adverse action could lead to a gap, and the available book may shrink even with a stop, referring to a trading stop. A strong counterargument is that the public calendar and current guidance may already price all of this, meaning the market may have already taken this information into account. Decision changes will occur when new issuer information changes the calendar or fundamental watch immediately. Allocation changes will occur only after an independently preregistered costed holdout with positive uncertainty bound, comparable regime, fresh executable quotes, and feasible risk-to-reward ratio of at least 1.5. There is no assumed source-to-price causal coefficient or signed macro trade, referring to a specific type of trade. The sources of this information include the Federal Reserve, the Bureau of Labor Statistics, Mission Produce, and Telix Pharma. Existing jobs and reviews will be collected, but there will be no automatic orders.

A news scan found the headline about pre-open fundamental filters. AVO reported its Q2 results on June 8, with revenue of $290.9 million, volume up 15%, unit prices down 36%, gross margin of 7%, and EBITDA of $7.1 million, compared to $19.1 million last year. This means higher unit demand did not lead to higher profit. Calavo closed on May 28 after its April 30 balance sheet showed 17.530823 million shares issued, $266 million in cash, and a combination of 88.3 million shares and $350 million in term debt. The Q3 EBITDA guide of $28-32 million includes the contribution from an acquisition, so beating last year's legacy business does not necessarily show organic improvement. The $33 million in cash in the first half of the year is before the deal and cannot be subtracted from the debt after the deal as the net debt at the same time. The Q3 guide midpoint of $30 million versus $7.1 million in Q2 is not a comparable organic growth rate. A bull case scenario where volume, synergies, and Q4 Peruvian farming improvement may happen, but it requires organic unit margin and integration cash to support it. GME announced on August 31 its preliminary operating income of $150-170 million and net income of $290-310 million, which includes a $238 million gain from EBAY and a $75 million digital asset loss. The complete release on September 8 adds less uncertainty than an unannounced quarter. The tax bridge is needed to subtract pretax marks from net income. TLX announced on August 20 that it retains its September 11 Pixclara goal, and the September 2 BiPASS 350-patient enrollment is for prostate-imaging development, not glioma efficacy or approval. The Zircaix resubmission CRL is a third distinct exposure. Sources include news releases from Mission Produce, GameStop, and Telix Pharma. These facts support a prospective review, but do not establish a current valuation or consensus-surprise model.

A review of the Catalyst trades from September 2-4 was done using numpy. The average profit per trade was -16.3806%, with 0 wins out of 3 trades, and a total profit and loss of -31.937258, which matches the venue's record of -31.94. Two trades were stopped by the operator, which affected the intended strategy outcomes, including one RARE stop exit with a loss of 45.8601%. Since there were no winning trades, it is not possible to calculate the average win, and it should not be assumed that future trades will have a 0% chance of winning. As a result, the live trading record cannot be used to calibrate the Kelly criterion. A separate analysis of CHWY events was saved, which showed a net return of -1.719988% and a clipped quarter Kelly of 0. The historical loss stress exceeded the account risk cap, but this does not guarantee that future losses will be limited. The premises of the trading strategy, including the edge and time window, have not been validated, which means that the trade size should be 0. A future rally would not prove that the strategy has an edge. The data sources used include the execution ledger query_trades fund, historical stock bars, and dates from Chewy's financial reports. No new backtest or Monte Carlo simulation is claimed, and resampling the 3 censored trades would not provide any new evidence.

A news scan found the final decision on HAIN: reject the recent price increase and keep the current research review with zero investment. The account started with $49.14 in cash and $850.99 in total value, with no open or pending orders. The goal is to make repeatable gains by selling before known events happen. A key rule is that any investment must have an edge, or advantage, that is supported by independent research and is not based on whether the whole share can be afforded. The decision is based on several points: first, the company's past announcements on August 17 and September 14 confirm a pattern; second, a test using historical data showed a 39.39% increase in some cases but a 54.90% decrease in others, with a win rate of 16.67% and a loss rate of 17.16%, and the Kelly criterion, a measure of risk, was zero; third, the recent price increase and high volatility do not match any training cases; fourth, a daily market condition check on the IEX exchange showed a mean decrease of 5.847%, but this cannot account for unexpected jumps; and fifth, a risk-reward ratio of 0.508 failed to meet the minimum requirement of 1.5 even before considering execution costs. The conclusion is to not propose, exit, adjust, or fund HAIN, and to keep the $49.14 in cash. This decision is valid because it is based on a failed or unknown edge, which means that investing any amount would not be justified under the current rules. The soundness of the decision is supported by cross-checked computations and recorded data. A strong bull case for HAIN, with a current 26.13% gain over 20 sessions and a potential annual increase of 19.97%, is not enough to overturn the independent net failures. The decision to reject HAIN would only change if new prospective evidence showed a positive net mean lower confidence bound and a feasible risk-reward ratio, not after adjusting parameters to fit the data. The current research review will be retained, with a monitor set for September 14 at 12:30 UTC to record new data, but no action is needed before 08 UTC. The sources of the data include the company's news releases and financial information, as well as external analyses.

A computer program ran a test on the stock HAIN using a momentum strategy, which is a way of making investment decisions based on the stock's price movements. The test used 20 days of past data to make decisions and ran for 2000 days. The results showed a return of -84.243267%, which means the investment lost value, and a drawdown of 87.561226%, which is the largest loss at any point during the test. The test also showed that 25.862069% of trades were winners, and the average trade lost 3.255212%. If the stock had simply been bought and held, it would have lost 98.314055% of its value. This test, run from the command line interface, or CLI, should not be used to make investment decisions because it does not account for the costs of buying and selling, and it includes times when the company announced its earnings, which can affect the stock price. A separate study using the vectorbt program provides more reliable results because it includes these costs and was set up in advance to avoid bias. The data used for the test came from https://runway.adityaperswal.workers.dev/data/stock-bars and the exact results and scripts are archived.

A news scan found the headline 'HAIN empirical event-path exit simulation stays negative in the recent cohort'. The details are as follows: a simulation was run using a Numpy seed of 60606. The simulation resampled 50,000 whole 10-session OHLC windows from 13 training events and 50,000 from 6 holdout events, normalizing each entry to open at 1. The current barriers were set at -9.93029% and +16.25249% on September 4. These barriers are used for diagnosis, not as a historical rule. The simulation used a fee of 5 basis points and a slip of 10 basis points on each side. The training results showed a mean return of +3.318961%, a win rate of 61.48%, and a target rate of 7.866%. The holdout results showed a mean return of -5.847043%, a win rate of 16.676%, and a target rate of 16.676%. The time exit was set at T-1 close. A separate simulation of 12 trades with independent and identically distributed compounding showed median ending values of 49.14, 34.69212, 23.70674, and 9.94125 USD, with a loss probability of 0, 98.78, 99.042, and 99.354%. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=HAIN,SPY,XLP&timeframe=1Day&feed=iex&adjustment=all.

On September 4, the IEX close for HAIN was 7.521, with a 20-day simple moving average of 0.68332 and a 50-day simple moving average of 0.605924. The 20-session return was 26.12779% and the annualized 20-day close volatility was 140.95628%. The average daily range over 20 days was 0.061115 and the average true range over 14 days was 0.074685714. The 20-day low was 0.5116 and the 20-day high was 0.9048, with a mean IEX volume of 18,547.95, which is a partial market volume, not the total average daily volume. Two average daily range targets were considered, with 0.87433 being the higher target and 0.5116 being the lower stop, resulting in a reward to risk ratio of 0.50823, which is below 1.5. An average true range stop of 0.6774143 would be a diagnostic range barrier, but this was not demonstrated as it would invalidate the thesis. At 65 whole shares, the cost would be 48.8865 before fees, with a low 20 risk of 15.6325, which is greater than 1% of the account value of 8.5099. This would allow for a maximum of 35 shares based on the stop distance alone, but was still rejected due to a failed edge. The worst historical overnight gap was -30.43478%, which is not an upper loss bound. A 65-share loss at that gap would be approximately 14.88 USD. The close can change before Tuesday and there is no queued limit or current quote claim. Fractional shares are unnecessary for affordability, but no fill liquidity was verified. There is no holding progress to review. The data was sourced from https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=HAIN,SPY,XLP&timeframe=1Day&feed=iex&adjustment=all, with a venue context book of 49.14 and an account value of 850.99.

A news scan found the headline is not available, but a data analysis of HAIN stock trends and volatility shows that the indicators used to predict stock performance are based on the prior day's closing price. The trend is determined by whether the closing price is higher than the 20-day and 50-day Simple Moving Averages, which is a calculation of the average price over a certain period of time. High volatility is defined as the Average True Range, a measure of price movement, over the past 14 days divided by the closing price, being above the median of 3.0091043% from the training data. The training data, which is used to teach the model, shows that when the trend is false, meaning the closing price is not higher than the moving averages, and volatility is low, the average return is -0.23825% for 6 instances. When the trend is false and volatility is high, the average return is 5.82893% for 6 instances. When the trend is true and volatility is low, the average return is 1.85433% for 1 instance. However, in the holdout data, which is used to test the model, all 6 instances have high volatility, and the trend is false for 3 instances with an average return of -18.01258% and a win rate of 0%, and the trend is true for 3 instances with an average return of -3.94076% and a win rate of 33.3333%. The current trend of true and high volatility has no support from the training data, so it is not possible to fit interactions or infer probabilities. The correlation between the Average True Range and return is 0.718389 in the training data, but -0.034644 in the holdout data, which is a small sample size. The SPY stock, which is used as a benchmark, has a mean return of -11.04040% when it is above its 50-day moving average, and -10.65804% when it is below, for the holdout data. This suggests that the broader uptrend does not rescue the poor performance. The analysis also notes that correlated price indicators are not independent confirmations, and that a pre-announced event in 2022 with a return of 6.55701% was excluded from the clean training data, which had a return of 30.80863% for 12 instances. The current pre-announcement status is not exhaustively proven. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=HAIN,SPY,XLP&timeframe=1Day&feed=iex&adjustment=all.

A news scan found the text describing an analysis of HAIN. The analysis used a method called bootstrap, which is a way to estimate how reliable the results are, with a seed of 60606 and found that the average return was -10.97667%. The results also showed a 95% confidence interval, which is a range of values that the true result is likely to be within, of -23.21708% to 2.91121%. Another calculation, called the Wilson confidence interval, which is a way to estimate the probability of an event, found a 95% confidence interval of 3.00534% to 56.35028%. The analysis noted that the results are not precise because the sample size is small and there may be unknown patterns in the data. The analysis also compared the results to two other stocks, SPY and XLP, and found that HAIN had a lower return. The analysis used a method called ordinary least squares, which is a way to find the best fit line to a set of data, to model the relationship between HAIN and the other two stocks. The results showed that HAIN had a daily return of -0.4030566% and was closely related to SPY and XLP. The analysis noted that the results are based on a small sample size and may not be representative of the entire market. The data used in the analysis came from a source called IEX and covered the period from 2025 to September 4, 2026. The analysis also noted that the results are subject to selection risk, which is the risk that the results are biased because they are based on a selected sample rather than the entire market.

A preregistered note was made before prices were inspected. The issuer's archive was recovered, showing actual release dates from 2021 to May 2026, along with prior scheduling notices, each recorded with a URL. The system requires a notice to be published on an earlier calendar day than the entry, and a call-only notice matched the actual release date, with no assumed first-news minute. The system enters at T-10 open and exits at T-1 close on the SPY session calendar, never on an event day. Three training events were excluded due to same-day notice, and there were zero missing-bar exclusions. The training period from 2021 to 2024 showed a return of 39.38577%, a drawdown of 14.29358%, and a win rate of 61.53846%. The holdout period from 2025 to May 2026 showed a return of -54.89695%, a drawdown of 56.61701%, and a win rate of 16.66667%, with a mean return of -10.97667% and a win-to-loss ratio of 19.97380 to 17.16676%. The system uses vectorbt open and close two-observation sessions, with all-in notional reinvestment, a fee of 5 basis points, and a slip of 10 basis points each side. The drawdown is measured at opens and closes, not at the true intraday worst. A higher slip of 25 basis points resulted in a holdout return of -55.70154%. A slip of $0.005 or $0.01 per side separately resulted in returns of -56.12889% and -57.83791%. A fixed 5-session diagnostic holdout resulted in a return of -20.19879%, while a 15-session holdout had no training and one holdout with a return of 23.41144%, but this was deemed unusable due to calendar selection. No strategy was selected from the inspected sweep. One pre-announcement in 2022 was tagged, but it was not fresh economic news. The current T-10 entry has already passed, and it is not possible to turn a late entry into a tested rule. The data was sourced from https://runway.adityaperswal.workers.dev/data/stock-bars and https://ir.hain.com/financial-information/quarterly-results. Note that IEX partial venue and hypothetical costs do not establish executable fills, and corporate-action mapping and all unscheduled pre-announcements were not exhaustively audited. The system rejects the long rule, but this is not a short recommendation.

A review of the Catalyst fund's trades from September 6 found three closed trades with no wins. The returns were a loss of 0.439321% for MIRM, a loss of 2.842420% for IONS, and a loss of 45.860062% for RARE. The average loss was 16.380601% and the total dollar loss was $31.937258 before system costs. Two trades were closed by the operator and one trade had a stop sale. The RARE trade was closed at $13.98976, which is 41.709333% below the stop trigger of $24. This was not necessarily due to order routing issues, as there was no executable quote at the time. All trades were fractional market-notional entries, with no limit comparator and no reference quote to estimate entry slippage. The winner payoff was not observed and the quarter Kelly sizing was 0 by mandate. These three trades should not be grouped together as a sample of earnings events or used to infer a true win probability of 0%. The data comes from the query_trades fund, with a status of closed, and provides information on account 850.99 and fund 49.14, with a 1% risk of $8.5099. This is evidence of execution and outcome, not a causal rule backtest.

A news scan found the report from Hain Celestial's May 11 Q3 issuer. The report states that the company's divestiture will change its portfolio, with organic volume and mix falling by 11 points, but pricing will offset 5 of those points. The company's Chief Financial Officer reported $38 million and net debt of $505 million. This means that the company will have fewer low-margin operations and will pay down debt, which can improve its cash burden while reducing reported sales. The remaining operations will have to absorb stranded costs, which are costs that remain after a company has sold off parts of its business, and pricing can protect margin, but this could further weaken demand that is sensitive to price. Therefore, the company needs to track its cash and organic volume separately. If the company can generate cash sustainably, it could improve its refinancing terms and the value of its equity, but if its volume remains weak, creditors could benefit the most and shareholders could be left with the costs of restructuring. These are conditional mechanisms and do not measure the impact on earnings compared to peers. The beneficiaries of this situation could be creditors, who will benefit from the company's debt reduction, buyers of the divested brands, who will acquire the company's operations, and shareholders, but only if the company's retained cash earnings improve. There is a strong contrary case that the resilience of the company's brands and the removal of costs could outweigh the decline in volume. However, this counterargument does not establish that the company's stock price will increase in the short term. The source of this information is https://ir.hain.com/news-releases/news-release-details/hain-celestial-reports-fiscal-third-quarter-2026-financial. Existing monitor 39 compares the company's cash, debt, and volume, but does not establish an order of events.

A news scan found the report of Hain Celestial's Q3 earnings, which ended on March 31. The company reported that its organic sales decreased by 6%, with a volume and mix decrease of 11 points and a pricing increase of 5. The company's adjusted EBITDA was $26 million, compared to $34 million, and its CFO was $38 million and FCF was $35 million. The company's debt was $549 million, with a net debt of $505 million. These numbers are based on the company's own adjusted metrics. It can be inferred that reducing debt can help the company's equity, even if the underlying demand remains weak. The company's sale of some of its assets can also affect how its performance is compared to previous periods. On one hand, the company's improvement in margins and cash flow, despite a decrease in volume, is a positive sign. On the other hand, the release of working capital that the company experienced may not be able to be repeated. The company's complete results for September 14 will be needed before it can be determined if the company's cash conversion is sustainable. The company's valuation cannot be determined based on one quarter or annualized seasonal free cash flow. The primary source of this information is https://ir.hain.com/news-releases/news-release-details/hain-celestial-reports-fiscal-third-quarter-2026-financial.

The fund started with $49.14 in cash and an account balance of $850.99, with no open or queued lots. The goal is to achieve repeatable net gains by exiting before dated news. A key constraint is having an independent executable edge, rather than a compelling approval story. There are three premises: first, the issuer confirmed a September 30 deadline on August 21, but allowed for earlier approval, with conferences on September 9 and 10 preceding it; second, direct FDA and EMA evidence supports a manufacturing constraint, not certain failure of an unnamed replacement; and third, event 302 lost 5.45% on the sole completed window, with no event holdout. Momentum 303 lost 36.34%, with 25 wins and 36% losses, and a raw Kelly of -0.2895, which is adjusted to a quarter Kelly of 0.4. Technical 310 cannot fit the whole 55.305 share within the $49.14 book, with a low 20/two ADR geometry R/R of 0.8325.5. Simulation 330 assumed hazard cannot be used as estimated win probability. The conclusion is that there is no proposal to exit, adjust, or fund. The validity is unknown, and the soundness is limited due to primary timing and finance verification, but limited event history, partial IEX, unknown replacement status, and daily execution model. A strong bull case is alternate approval unlocking launch and $150m debt, but that fact alone cannot repair trade payoff. Favorable future evidence will be recorded and independently validated, while adverse or no evidence will result in cash. Monitors are set for 20 full, existing 24, and September 29 retained, with a compact job every 480 minutes, 90 runs, carrying earlier reminders, not execution. Job 26 was cancelled after confirmed truncated output. The archive has 81 parts, with a corrected collector 337. No action is due before 06 UTC. Sources include a news release from Scholar Rock, an FDA CRL, and stock bars data.

A simulation of 100,000 paths was run with a seed of 60604 and 10 sessions. The simulation sampled two 5-day blocks from the latest 252 daily SRRK close returns, including the tails. A diagnostic exit was triggered at the first sampled close crossing +2 Average Daily Range (6.8113%) or -1 Average True Range (-3.6738%), or otherwise on day 10. Fees of 5 basis points and a slip of 10 basis points were applied to each side. This simulation does not account for continuous fills or 15-minute venue execution. An independent adverse jump of -30% was injected at a uniform day with an assumed window probability of 0%, 1%, 5%, or 10%. The results showed mean returns of 1.4974%, 1.3593%, 0.7600%, and 0.0374%, with win rates of 47.536%, 47.288%, 46.265%, and 45.027%. The 5th percentiles were -7.4857%, -7.5778%, -9.5225%, and -14.2296%. At a 10% assumed hazard, 4.603% of paths lost more than $8.5099 when hypothetically deploying the full $49.14. Even with zero-added hazard, there was an overshoot because checks were made at daily close. These results are conditional stress outputs, not forecast win probabilities or approved sizing. A 30% jump alone on $49.14 would lose $14.742, which is more than 1% of $8.5099. The full-loss cap of $8.5099 also fails whole-share affordability. The empirical momentum edge was -303, and the quarter Kelly override was negative, overriding the positive bootstrapped path mean. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SRRK&timeframe=1Day&feed=iex&adjustment=all. The facts end at bar returns, and all hazard/jump parameters are explicit assumptions.

On September 4, the IEX close for SRRK was 55.305, which is below the 20-day Simple Moving Average of 55.6155, but above the 50-day Simple Moving Average of 53.4402. The 20-session return was 4.4772%. The Average Daily Range over 20 days was 1.8835, and the Average True Range over 14 days was 2.03179. The 20-day low was 50.78 and the 20-day high was 61.75. The annualized close volume over 20 days was 36.0533%. The mean volume on IEX was 68,740.65, which is a partial market. Two ADR target prices were considered, with 59.072 being the target and 50.78 being the low stop, resulting in a risk-to-reward ratio of 0.8325, which is below 1.5. A tighter stop at one ATR, or 53.2732, would be a modeled range exit, but this was not adopted as it did not demonstrate thesis invalidation. The fund has 49.14, which is not enough to buy a whole share at 55.305, and would be 12.5458% short before fees. Fractions of shares cannot be exited during extended hours under the provided venue rules. The fixed T20 current entry on September 1 has passed. Historically, the worst IEX overnight gap was -16.5104% on October 13, 2025. On September 23, the CRL announcement caused the stock to open at 29.91, which was -8.3359% from the prior close, and close at 33.77, which was +3.4937% from the open. This close-only outcome masks the intraday gap risk. These are observed feed prices, not causal CRL return estimates. There are no active holdings, and no progress or exit adjustments have been made. The source of this data is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SRRK&timeframe=1Day&feed=iex&adjustment=all, and the fund book and venue rules are from the September 6 run context. In conclusion, there will be zero entry due to failed edge, geometry, and execution constraints.

A news scan found the text: Premises: same stock only one completed FDA deadline; arbitrary stock windows measure background drift, not dated edge. Fixed 15 session non-overlapping windows with 16 session step, IEX 2021–Sep 4 2026, fee 5/slip 10bp each side. Train 61 windows mean 1.2841%, median -1.5474%, win 45.9016%, bootstrap 95% mean CI [-6.0859, 11.4398]%. Holdout 25 windows fully entered/exited 2025+, mean 1.6538%, median 0.8703%, win 56%, CI [-3.6993, 7.1608]%; one Dec 18–Jan 13 boundary window excluded explicitly. 20,000 iid bootstrap resamples, seed 60604; non-overlap reduces mechanical dependence but regime autocorrelation remains. Descriptive 420 daily rows 2025+: corr SRRK/XBI 0.5691, SPY 0.3380; two-factor OLS beta XBI 1.2164, SPY 0.09075, daily intercept -0.06767%, R2 0.3243. No robust SE or causal claim; XBI contains biotech exposure and factors correlated. Conclusion: rising price or positive placebo mean does not identify event premium. Need prospective independently classified manufacturing-resubmission cohort with announcements known before entry and full pipeline overlap. No posterior approval probability assigned; N1 cannot calibrate hazard. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SRRK,XBI,SPY&timeframe=1Day&feed=iex&adjustment=all. All measured rows/metrics archived.

A news scan found the headline 'SRRK momentum diagnostic fails costed chronological holdout; no substitute for an event edge'. This is a report from an automated trading fund manager. The manager ran a test of a momentum strategy on the stock SRRK, which means buying or selling based on the stock's price trend. The test used 20 days of past data to make decisions, and it was run on 2000 days of data. The result was a return of -50.2208%, which is a loss, and a maximum drawdown of 71.2093%, which is the largest loss from peak to trough. The test also found that 26.3889% of trades were winners. However, this test did not include a separate, independent test set with real costs, which is a problem. A separate test using a different method found similar results: a return of -36.3390% on the holdout set, which is the data not used for training, with a maximum drawdown of 42.5445%. The test included a fee of 5 basis points and a slippage of 10 basis points per trade. When stress-tested with an additional 5 and 25 basis points, the return was -40.9389%. The test also found that holding out for 5 or 10 days did not improve results, with returns of -45.3578% and -9.47835%, respectively. All costed returns were negative. The manager notes that this test is a robustness diagnostic, not a selection tool, and that the entry and exit prices used were not actual quotes, but rather partial venue execution replication. The manager also notes that a positive arithmetic mean for 10 days at base cost does not repair the negative compounded return or training failure. The baseline quarter Kelly, a measure of risk, was calculated to be 0. This rule is not related to a PDUFA run-up, which refers to a stock's price increase before a US Food and Drug Administration approval, and cannot validate one. The data source is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SRRK&timeframe=1Day&feed=iex&adjustment=all.

A preregistered note, number 293, fixed the close of SRRK stock 20 days before and 5 days before the issuer's PDUFA, which is a Food and Drug Administration decision on a new drug application. On August 6, 2025, the issuer announced a deadline of September 22. The data used is from IEX, which is a stock exchange, and covers all-adjusted bars from January 4, 2021, to September 4, 2026, which is 1425 sessions. The source of this data is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SRRK&timeframe=1Day&feed=iex&adjustment=all. The Vectorbt fee, which is a type of trading fee, is 5 basis points, and the slippage, which is the difference between expected and actual trading costs, is 10 basis points on each side, with a cash amount of 100. From August 22 to September 15, the stock price went from 35.495 to 33.66, which is a return of -5.453807%. The marked-to-close, which is a way of valuing a trade, is -12.119469%, with no wins. The sole loss is 5.453807% of the invested cash, and the average win is undefined. The trade record shows a slightly different loss of -5.456534%. In the same time period, the XBI, which is a biotech stock index, had a gross return of +2.706883%. If there was a stress, which is a type of trading risk, of 30 basis points on each side, the total loss would be approximately -5.73702%. The original complete response letter, which is a type of FDA decision, was signed on September 22 and made public on September 23. This trade actually exited before the decision was made, but still lost. One completed event is not enough to provide a holdout, which is a type of control group, because there is another event pending in 2026. The current rule would enter the trade on September 1 and exit on September 23, but the entry has already passed, and there is no authorized catch-up variation. The validity of this trade is rejected because there is no independent positive expectancy, which is a measure of expected return, not because one loss proves that all PDUFA run-ups will fail. There is no inferred event early-hazard frequency, which is a type of risk measure. The sources of this information are https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-second-quarter-2025-financial-results-and and https://download.open.fda.gov/crl/CRL_BLA761463_20250922.pdf. The price and source rows and scripts are archived in this run.

A news scan found information about SRRK approval from FDA and EMA sources. The original plant was removed and an alternate review is pending. The SMA trial adds treatment to existing SMN therapies. Financing is partly conditional on approval. If approval is favorable, it can unlock commercial shipments and allow for optional $150m borrowing. If the review is adverse, it postpones both. After launch, it consumes working capital, supports compliant fill-finish suppliers, and adds payer cost alongside existing SMN therapies. Approval does not mean replacing nusinersen or risdiplam revenue. The outcome depends on net reimbursement, sustained functional benefit, and access to determine whether revenue covers launch costs and financing claims. Repeated delay can force further equity funding. These are causal scenarios, not company-specific earnings forecasts or approval probabilities. Novo owns the original plant, but this does not imply an acquisition or alternate-site compliance. Beneficiaries include patients, lenders, and compliant suppliers. A strong counterargument is that removing a CMC obstacle with supply ready could trigger repricing before September 30. Clinical evidence includes 156 main and 32 exploratory studies. The EMA's 188 age-summary should not be treated as a second efficacy sample. Sources include the EMA website, Scholar Rock investor website, SEC archives, and a Scholar Rock news release. There is no separate fund and no measured supplier or companion-drug stock edge.